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It has long been recognized that hepatocellular carcinoma heterogeneity arises from variation in the
microenvironment or from genomic alteration. Only recently it has become clear that non-genetic alterations,
such as cytoskeletal rearrangement, protein localization and formation of protein complexes, are also involved in
generating phenotype variability. These proteome fluctuations cause genetically identical cells to vary significantly
in their responsiveness to microenvironment stimuli. In the cirrhotic liver pre-malignant hepatocytes are
continuously exposed to abnormal microenvironments, such as direct contact with activated hepatic stellate cells
(HSCs) and extracellular matrix components. These abnormal environments can have pronounced influences on the
epigenetic aspects of cells, translating into abnormal phenotypes. Here we discuss non-genetic causes of
phenotypic heterogeneity of hepatocellular carcinoma, with an emphasis on variability of membrane protein
complexes and transferred functions raising important implications for diagnosis and treatment.
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Introduction
Hepatocellular carcinoma (HCC) is the third leading
cause of cancer mortality worldwide and a significant in-
crease in the incidence of HCC through the last two de-
cades has been observed [1]. There are two prominent
features in the development of HCC. First, 90% of HCCs
have chromosomal abnormalities and, second, the great
majority of these tumors, regardless of aetiology, develop
in cirrhotic livers, which are characterized by destruction
of the hepatic lobular architecture and its replacement
by nodules containing proliferative hepatocytes, in the
presence of chronic inflammation and fibrosis [2].
A seminal feature of hepatocellular carcinoma is the
ability to produce multiple subpopulations of cells with
diverse genetic, biochemical and immunological charac-
teristics [3,4]. How this heterogeneity emerges and how
it is maintained is not clear [5,6]. Fluctuations in single
cells can be masked or completely misrepresented when
cell populations are analyzed. Therefore, intra-tumor* Correspondence: vinicio.carloni@unifi.it
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distribution, and reproduction in any mediumheterogeneity may foster tumor evolution and adapta-
tion and hinder personalized-medicine strategies that
depend on results from imaging procedures or single
tumor-biopsy samples [7,8]. Along these lines, it has be-
come exceedingly apparent that the utility of measure-
ments based on the analysis of bulk tumors is limited by
intra-tumor genetic and epigenetic heterogeneity, as
characteristics of the most abundant cell type might not
necessarily predict the properties of the whole cell popu-
lations [8]. Indeed, this aspect is supported by a recent
report describing the presence of distinct diagnostic sig-
natures derived from different biopsies of the same
tumor [9]. Yet, such non-uniformities often unveil mo-
lecular patterns that can represent mechanisms of tumor
progression. More interestingly, variability among single
cells in a population may arise from different responses
to intrinsic and extrinsic perturbations coming from the
abnormal microenvironment that may have pronounced
influences on the epigenetic aspects of cells, translating
into abnormal phenotypes [10]. Therefore, it is tantaliz-
ing to hypothesize that normalization of the tumor
microenvironment corresponds to the normalization of
cellular phenotypes, and destabilization of normal tissue
organization can translate into an increased risk ofd Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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The great interest concerning the tumor microenvironment
is associated with the recognition that micro-environ
mental alterations are not just passive consequences of
genetic evolution occurring in hepatocytes, but that
they are active participants in tumorigenesis [13]. As many
excellent reviews summarize progress in this area, we
focus on the effects of micro-environmental alterations
on the phenotypic heterogeneity of pre-malignant
hepatocytes.
Activated hepatic stellate cells
Pre-malignant hepatocytes live in a complex micro-
environment that includes the extracellular matrix
(ECM), diffusible growth factors and cytokines, and a
variety of non-epithelial cell types, including endothe-
lial cells, activated hepatic stellate cells (HSCs), and
those that can respond to infection and injury, that is,
lymphocytes, Kupffer cells-macrophages and mast cells
[14,15].
HSCs are known as very important ECM-producing
myofibroblasts dwelling in the cirrhotic liver and micro-
environment of HCC. The activated HSCs infiltrate the
stroma of liver tumors and localize around tumor sinu-
soids, fibrous septa and capsules [16,17]. Activated
HSCs increase the production and secretion of ECM
proteins, which include collagens, laminins, fibronectin
and heparan-sulphate proteoglycans. In this way, HSCs
have a major impact on the ECM content of the micro-
environment and also may affect the overall tumor stro-
mal behavior and vice versa [18]. Indeed, several studies
demonstrated that transformed hepatocytes stimulate
migration of HSCs in culture, as well as their produc-
tion of ECM components, when co-cultured, or when
HCC tumor-conditioned medium was used [19-21].
Hence, all support the concept that hepatocarcinoma
cells recruit HSCs, which then promote tumor growth
and local invasion [22]. The cancer cell-induced in-
crease in ECM synthesis is mediated by transforming
growth factor beta (TGF-β1), whereas proliferation of
HSCs is promoted by platelet-derived growth factor
(PDGF) [23,24]. This interaction, between HCC and
HSCs, is bidirectional since HSCs, in turn, stimulate
hepatocarcinoma cell proliferation and inhibit their
apoptosis to increase the population of cancer cells [25].
Proliferation of hepatocytes is mediated by factors secreted
by activated HSCs, such as insulin-like growth factor I
(IGF-I), transforming growth factor alpha (TGF-α), hep-
atocyte growth factor (HGF) and other inflammatory cyto-
kines [26,27]. Accumulating evidence indicates and points
to an important and major influence of activated HSC on
HCC development and progression and, hence, the thera-
peutic inhibition of activated HSCs should be taken into
account when treating HCC [28].Premalignant and cancerous hepatocytes
Hepatocyte plasma membrane microdomains, the
tetraspanin paradigm
It has long been recognized that differences from one
cell to the next can arise through variation in the extra-
cellular environment or from genomic alteration. Only
recently it has become clear that plasma membrane pro-
tein fluctuations can also have profound effects on
phenotype. These fluctuations cause genetically identical
cells to vary significantly in their responsiveness to stim-
uli of the fibrotic microenvironment (Figure 1).
The spatial organization of plasma membrane compo-
nents in discrete microdomains is thought to be a key
factor in the generation of distinct signal inputs or out-
puts [29]. Dynamic microdomains have important impli-
cations for understanding how signaling complexes are
assembled and disassembled in response to ECM stim-
uli; some components of these signaling complexes
might reside permanently in these microdomains, but
others could have extremely transient interactions [30].
Tetraspanins are transmembrane proteins defined by
small and large outer loops, short N-terminal and C-
terminal tails with four transmembrane domains. They
form complexes termed tetraspanin-enriched micro-
domains (TEMs) by interacting with other tetraspanins
and with a variety of transmembrane and cytosolic pro-
teins that are required for their function [31]. Several
tetraspanin molecules have been identified and impli-
cated in the regulation of cell proliferation, cell migra-
tion and cell fusion [32]. The most important partners
are integrins, particularly α3β1, α4β1, α6β1 and α6β4,
intracellular associated heterotrimeric G proteins, prote-
ases, immunoglobulin superfamily members and cytosolic
signal transduction molecules [31]. The repertoire of
tetraspanins differs between cancer cell types; therefore, a
complete characterization of tetraspanin-associated pro-
teins and functions is difficult to accomplish and may not
be generalized. Nevertheless, in the majority of cancer cell
types, including HCC, a characteristic feature is the evi-
dent presence of integrins, signaling proteins and prote-
ases as important components of these domains [33].
Tetraspanin CD81
Tetraspanin CD81 was identified originally as the target
of an anti-proliferative antibody (TAPA-1) that inhibited
in vitro cellular proliferation [34]. CD81 is involved in a
broad range of cellular functions as revealed by the bind-
ing of monoclonal antibodies. The antibodies evoke their
effect by mimicking a natural ligand or by altering the
interactions between CD81 and its associated proteins. Al-
though the protein is widely expressed, its levels within a
single tissue vary in response to cellular activation. An im-
portant feature of tetraspanin CD81 is its ability to associ-
ate with itself forming homodimers and with various other
Figure 1 Interaction among factors that determine phenotypic heterogeneity in HCC. Combinations of environmental, genomic and
proteomic variation can cause heterogeneity in an initially homogenous population of pre-malignant hepatocytes.
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CD81 in pre-malignant hepatocytes can contribute to re-
organizing the plasma membrane in domains where sig-
naling proteins can be recruited [35]. CD81 regulation of
proliferation is positively associated with activation of the
extracellular signal-regulated kinase 1/2 (ERK1/2)/MAPK
pathway. CD81 overexpression can activate ERK1/2 while
promoting proliferation [35]. Importantly, CD81 induces
reorganization of the plasma membrane amplifying the
instability of pre-malignant hepatocytes and enhancing
their neoplastic progression. Therefore, phenotype hetero-
geneity could be influenced primarily by a fluctuation of a
single protein and associated factors organized in discrete
plasma membrane domains. These membrane micro-
domains represent versatile devices for compartmentaliz-
ing different signaling functions. In the non-activated state
they float freely, carrying a few passenger proteins, but,
when activated, they coalesce to form larger platforms
where proteins meet to transfer functions in signaling,
processing and transport [36].
When the hepatocytes progress in their transform-
ation, the tendency of CD81 expression is to be lost, as
revealed by two clinical studies showing a decreased or
absent CD81 expression, particularly in metastatic tis-
sues [37,38]. HCC cells re-expressing CD81 are still
capable of proliferating and producing the principal
tumor when injected into the liver of nude rats; how-
ever, they contain a defective faculty to produce tu-
mors in distant parts of the liver [39]. These findings
strengthen the vision that CD81 is a facilitator of cell
proliferation and in the meantime is a negative con-
troller/regulator of movement when expressed by the
cells. This is supported by the current view that cellgrowth and ability to metastasize are two conditions of
malignancy not necessarily overlapping [40].
Tetraspanin CD151
The initial evidence that CD151 promotes metastasis
came from a study showing that an antibody with un-
known specificity inhibited metastasis formation by a
human epidermoid carcinoma cell line in vivo. The anti-
body was found to recognize CD151, and inhibit cell
migration without affecting adhesion or proliferation
[41]. Overexpression of CD151 is seen in many tumor
types. In breast, pancreatic, colorectal and non-small-
cell lung cancer, high CD151 expression is associated
with a poor prognosis [33].
Overexpression of CD151 has been associated with
poor prognosis also in HCC. Some studies have indi-
cated that CD151 overexpression promotes the metasta-
sis/invasion of cancer cells by mediating integrin signals,
while others have argued that an increased expression of
CD151 contributes to activate phosphatidylinositol 3-
kinase/protein kinase Akt pathway [42]. Indeed, the high
expressions of CD151 and α6 integrin are major contrib-
utors to the invasion-prone phenotype of HCC. In con-
trast with CD81, the contribution of CD151 to HCC
metastasis/invasion provides an example of the facilita-
tor role of this tetraspanin (Figure 2). Apart from
CD151, the tetraspanin TSPAN8 (previously known as
CO-029, TM4SF3) has been also associated with tumor
progression [43]. Overexpression of TSPAN8 is de-
scribed on hepatocellular carcinomas that are poorly dif-
ferentiated and prone to intrahepatic spreading [44].
Conversely, down-regulation of tetraspanin CD82/KAI1
was observed at the levels of both mRNA and protein.
Figure 2 Tetraspanin-enriched microdomain variation as a component of HCC progression. The signaling pathway varies between cell
types when differential TEM profiling is expressed following exposure to a cell agonist or through changes in the microenvironment. These
variations in signaling can profoundly affect the tumorigenicity and metastatic properties of HCC cells. a) Following stimulation, CD81-associated
proteins inhibit tumor cell migration, possibly through a blockade of ezrin-radixin-moesin (ERM) protein activation, inhibiting actin reorganization.
b) Reduced expression of CD81 and up-regulation of CD151, α6β1 integrin and ADAM10 foster invasion and possibly metastases through events
of actin cortex - membrane destabilization during cell motility.
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ated HCCs. Importantly, the CD82/KAI1 level correlated
inversely with intrahepatic metastases [45].
Differences in integrin expression and signaling within HCC
The pattern of integrins expressed by human hepatocytes
is strikingly different from most other epithelial cells [46].
Normal adult hepatocytes express low levels of only three
integrins: α1β1, a collagen and laminin receptor; α5β1, a
fibronectin receptor; and α9β1, a tenascin receptor. In
contrast, other integrin receptors, such as α2β1, α3β1,
α6β1 and α6β4, are undetectable on normal hepatocytes.
One of the most frequent alterations during liver carcino-
genesis is the de novo expression of the integrin, α6β1.
HCC patients characterized by multiple tumors, vascular
invasion and the absence of encapsulation exhibit in-
creased α6β1 expression [47]. In fact, the induction of
α6β1 is an early event in hepatocellular carcinogenesis,
and it is reasonable to consider that α6β1 contributes to
hepatocarcinogenesis based on several lines of evidence
[48-51]. For this reason, it is important to understand the
mechanism by which the α6β1 integrin influences the
function of HCC cells. One likely possibility is that α6β1-
mediated activation of focal adhesion kinase (FAK) and
ERK1/2 controls signaling pathways important for HCC
function [52]. Both FAK and ERK1/2 are of interestbecause they are regulated by integrin-mediated at-
tachment to ECM, as well as growth factor stimulation,
and they control important functions of tumor cells, such
as growth and migration. Another possibility suggests that
overexpression of α6β1 could provide a ligand-independent
growth advantage by modulating the cellular architecture
or a signaling pathway required for cell growth [51].
Interestingly, the role of α3β1 integrin appears more
controversial in hepatocarcinogenesis. A previous study
indicated that TGF-β1 was able to induce a significant
increase in the expression level of α3β1, which consecu-
tively cooperated with TGF-β1 to induce HCC cell
epithelial-mesenchymal transition (EMT) [53]. In a re-
cent study, investigators could not confirm the previous
findings when evaluating α3β1 expression in HCC tissue
specimen of patients with high concentration of serum
TGF-β1 levels nor could be demonstrated a significant
up-regulation of α3β1 in HCC cells after 24 or 48 hours
of TGF-β1 stimulation. Indeed, they find that the ampli-
fied integrin α6β1 signaling pathway is able to induce
EMT of HCC cells [42].
ADAMs
ADAMs are multidomain proteins that contain a disintegrin
and a metalloprotease domain [54]. Their metalloprotease
domains can induce ectodomain shedding and cleave ECM
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have adhesive and fusion activities. Hence, ADAMs are
poised to modulate a variety of cell-cell and cell-ECM in-
teractions. ADAM10, a member of the ADAM family, was
detected in all human HCC tissues tested by immunohis-
tochemistry but not in normal liver tissues [56]. Moreover,
CD44, a typical substrate of ADAM10 protease, was also
expressed in all human HCC tissues but not in normal
liver tissues. These data suggest that overexpression of
ADAM10 and CD44 is a characteristic of human HCC.
Specifically, ADAM10 is involved in the intramembrane
proteolysis process, whereby it mediates ectodomain
shedding of various membrane-bound receptors, adhe-
sion molecules, growth factors and cytokines [57].
Conclusions
HCC cell phenotypes are the result of the integration of
inputs from genotype and environmental stimuli. Epi-
genetic changes that arise during tumor progression
alter and diversify cellular phenotypes, posing a major
obstacle to the understanding and clinical management
of HCC. We suggest that the phenomenon of intra-
tumor phenotypic heterogeneity, especially aspects that
are related to clonal diversity, deserve to be recognized
and accounted for during the analysis of HCC tumor,
building of experimental models and design of thera-
peutic approaches.
The dominance of gene-centric views has been chal-
lenged with the rapid development of research establishing
that because tumors contain phenotypically distinct popu-
lations of both tumor and stromal cells that interact in a
dynamic and reciprocal manner, these interactions are
likely to result in the emergence of different proteome
profiling. This aspect creates significant problems in
employing therapeutic procedures in which micro-
environmental changes make a procedure inefficient
and in some regions of the HCC a therapeutic result
may not be achieved. This inequality of therapy gives
HCC cells time to develop resistant phenotypes. In
addition, components of the microenvironment can ac-
tively protect tumor cells from treatment through se-
creted factors and cell contact-mediated pro-survival
stimuli. Heterogeneity in the tumor microenvironment
translates into heterogeneity of tumor cell phenotypes,
and so some tumor cells might be intrinsically less sensi-
tive to the therapy. Intra-tumor heterogeneity, associated
with heterogeneous protein function, may promote HCC
progression through Darwinian selection.
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